Emergent BioSolutions Inc. (EBS)
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
Emergent Biosolutions (EBS) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $1.44 per share a year ago.
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario
Emergent BioSolutions is showing signs of a potential turnaround with strategic restructuring, cost-cutting, and securing significant contracts in public health preparedness. Despite a challenging Q2, the company raised its full-year revenue forecast and is focusing on improving operational efficiency and reducing debt. Emergent's involvement in global health crises, like mpox, and securing FDA approvals and contracts, positions it as a key player in biodefense.
Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines
On Wednesday, Emergent BioSolutions Inc. EBS said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and mpox product portfolio.
EBS Stock Rises on FDA Nod for ACAM2000 in Mpox Indication
The FDA approves Emergent BioSolutions' sBLA seeking a label expansion of ACAM2000 for the mpox indication. Stock rises in pre-market trading.
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection
Thursday, the FDA approved Emergent BioSolutions Inc.'s EBS supplemental Biologics License Application (sBLA) for the expansion of the indication for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in individuals determined to be at high risk for mpox infection.
Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine
The FDA approves the company's smallpox vaccine for Mpox.
US FDA approves use of Emergent's smallpox vaccine for people at high risk of mpox
Emergent BioSolutions on Thursday said the U.S. Food and Drug Administration (FDA) had approved expanded use of its ACAM2000 smallpox vaccine to include people at high risk for mpox infection.
Emergent to donate 50,000 vaccine doses to address mpox outbreak in Africa
Emergent BioSolutions said on Monday it would donate 50,000 doses of its vaccine, ACAM2000, to the Democratic Republic of the Congo and other impacted countries of Burundi, Kenya, Rwanda and Uganda to address the current mpox outbreak.
Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
Emergent BioSolutions is a key player in public health. Its flagship product, NARCAN, is central to combating the opioid crisis. EBS stock rally is likely driven by its smallpox vaccine, ACAM2000, which has potential implications for monkeypox. Potential refinancing and strategic turnaround efforts mitigate the company's financial challenges, including significant debt and cash burn.
Why Emergent BioSolutions Stock Is Skyrocketing Today
The European Centre for Disease Prevention and Control raised its risk level for mpox on Friday. The World Health Organization declared a global public health emergency on Wednesday.
Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks
On Tuesday, Emergent BioSolutions Inc. EBS reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the consensus of $190 million.
Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript
